InflaRx (IFRX) Net Cash Flow Growth (1y) (2017 - 2026)
InflaRx (IFRX) Net Cash Flow Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 47.11% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.60% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -100.75% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2,045.25% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -104.22% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 149.49% |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -104.82% |
| Dec 31, 2025 | 213.69% |
| Sep 30, 2025 | -190.00% |
| Jun 30, 2025 | -447.80% |
| Mar 31, 2025 | 147.50% |
| Dec 31, 2024 | -12.95% |
| Sep 30, 2024 | 284.35% |
| Jun 30, 2024 | -134.97% |
| Mar 31, 2024 | 186.24% |
| Dec 31, 2023 | -616.19% |
| Sep 30, 2023 | 25.69% |
| Jun 30, 2023 | 167.99% |
| Mar 31, 2023 | -199.46% |
| Dec 31, 2022 | 97.65% |
| Sep 30, 2022 | 481.49% |
| Jun 30, 2022 | -166.21% |
| Mar 31, 2022 | -74.99% |
| Dec 31, 2021 | -146.72% |
| Sep 30, 2021 | -104.23% |
| Jun 30, 2021 | -161.51% |